Skip to main content

Advertisement

Log in

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Cemiplimab may significantly increase overall survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level of at least 50%. Therefore, there is a need to consider the cost-effectiveness of using this therapy for this indication.

Methods

This Markov model was built to estimate the cost and effectiveness of cemiplimab vs. chemotherapy in the first-line treatment of advanced NSCLC based on the data from the EMPOWER-Lung 1 trial. Life-years (LYs), quality-adjusted LYs (QALYs) and lifetime costs were estimated. One-way and probabilistic sensitivity analyses were performed to evaluate the model uncertainty. Additional subgroup analyses were performed.

Results

Treatment of advanced NSCLC with cemiplimab added 0.546 QALYs (1.492 LYs) and resulted in an incremental cost of $22,069.804 compared with chemotherapy, which was associated with an incremental cost-effectiveness ratio of $40,390.412 per QALY gained. The results of one-way sensitivity analysis found that the cost of cemiplimab was the most sensitive factor in our study. The probabilistic sensitivity analysis showed that the probability of cemiplimab being cost-effective was 100%. The subgroup analysis demonstrated that high PD-L1 expression (≥ 90%, > 60 to < 90% and ≥ 50 to ≤ 60%) also kept the incremental cost-effectiveness stable at $63,415.2450 per QALY, $61,896.446 per QALY and $–71,921.259 per QALY.

Conclusion

From the perspective of US payers, cemiplimab is cost-effective in the first-line treatment of advanced NSCLC at the willingness-to-pay threshold of $150,000 per QALY.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

    Article  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209.

    Article  Google Scholar 

  3. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.

    Article  Google Scholar 

  4. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39.

    Article  CAS  Google Scholar 

  5. Boyer M, Sendur MAN, Rodriguez-Abreu D, et al. (2021) Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol 2021:JCO2003579

  6. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.

    Article  CAS  Google Scholar 

  7. Burova E, Hermann A, Waite J, et al. Characterization of the Anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Mol Cancer Ther. 2017;16(5):861–70.

    Article  CAS  Google Scholar 

  8. Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153–8.

    Article  CAS  Google Scholar 

  9. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov identifier: NCT02760498. https://clinicaltrials.gov/ct2/show/NCT02760498, Accessed 18 Sep 2017

  10. Study of REGN2810 (anti-PD-1) in patients with advanced malignancies. ClinicalTrials.gov identifier: NCT02383212. https://clinicaltrials.gov/ct2/show/NCT02383212, Accessed 18 Sep 2017

  11. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.

    Article  CAS  Google Scholar 

  12. Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582–92.

    Article  CAS  Google Scholar 

  13. Sezer A, Kilickap S, Gumus M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604.

    Article  CAS  Google Scholar 

  14. Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112–8.

    Article  Google Scholar 

  15. GetData graph digitizer. Accessed Jan 2021. http://getdata-graph-digitizer.com

  16. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.

    Article  Google Scholar 

  17. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.

    Article  Google Scholar 

  18. Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw Open. 2021;4(1):2033761.

    Article  Google Scholar 

  19. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files.

  20. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.

    Article  CAS  Google Scholar 

  21. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–34.

    Article  CAS  Google Scholar 

  22. Hu H, She L, Liao M, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer. Front Oncol. 2020;10:1649.

    Article  Google Scholar 

  23. Engel-Nitz NM, Johnson MP, Bunner SH, Ryan KJ. Real-world costs of adverse events in first-line treatment of metastatic non-small cell lung cancer. J Manag Care Spec Pharm. 2020;26(6):729–40.

    PubMed  Google Scholar 

  24. Di Federico A, De Giglio A, Parisi C, Gelsomino F, Ardizzoni A. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: selecting the best strategy. Crit Rev Oncol Hematol. 2021;160:103302.

    Article  Google Scholar 

  25. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  Google Scholar 

  26. Chouaid C, Bensimon L, Clay E, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52.

    Article  Google Scholar 

  27. Barbier MC, Pardo E, Panje CM, et al. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ. 2021;22(5):669–77.

    Article  Google Scholar 

  28. Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–6.

    Article  CAS  Google Scholar 

  29. Konidaris G, Paul E, Kuznik A, et al. Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma: a cost-effectiveness analysis. Value Health. 2021;24(3):377–87.

    Article  Google Scholar 

  30. Ghetti G, D’Avella MC, Pradelli L. Preliminary cost-effectiveness and cost-utility analysis of cemiplimab in patients with advanced cutaneous squamous cell carcinoma in Italy. Clinicoecon Outcomes Res. 2021;13:121–33.

    Article  Google Scholar 

  31. Moreno V, Garrido P, Papadopoulos KP, et al. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021;155:151–5.

    Article  Google Scholar 

  32. She L, Hu H, Liao M, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88–94.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the participants of the study. Thanks to your hard work, our research was completed. Thank you again.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chongqing Tan.

Ethics declarations

Funding

The work was supported by grants from the National Natural Science Foundation of China (grant numbers: 82073818 and 71874209) and the Key Science-Technology Research and Development Program of Hunan Province (grant number: 2020JJ8046) and the Hunan Provincial Natural Science Foundation of China (grant number: 2019JJ40411). The Journal’s Rapid Service Fee was funded by the authors.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

LW is the first author and has completed the entire paper; YP and SQ contributed to the model; XZ, LP, SL, and XW gave me constructive advice and guided me in writing the paper. CT was the corresponding author and gave me the concept and design of the study during writing.

Disclosures

Liting Wang,Ye Peng, Xiaohui Zeng, Liubao Peng, Sini Li, Shuxia Qin, Xiaomin Wan and Chongqing Tan declare no conflicts of interest.

Compliance with Ethics Guidelines

This article is based on a retrospective study and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, L., Peng, Y., Zeng, X. et al. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%. Adv Ther 38, 4354–4365 (2021). https://doi.org/10.1007/s12325-021-01828-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-021-01828-1

Keywords

Navigation